ANX005 in Guillain-Barré syndrome (GBS): First-in-kind monoclonal antibody designed to block C1q and the entire classical complement pathway in both the body and the brain has the potential to be the ...
Amounts in US$ unless otherwise notedGenerates record quarterly net revenue of $280 million; an increase of 12% year-over-year led by ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback